Recursion works with Genentech on first validated neuro target found through its AI map

Aug 5, 2026 · Issue 1 · 2 sources, 2 articles

Recursion is working with Genentech to advance the first validated neuro target identified through its AI map. The 4.5-year AI partnership with Roche, worth up to $12 billion, was also mentioned in Hungarian-language reports.

Who is affected and how

pharmaceuticals

Validation of a target found through the AI map and the scale of the partnership gauge how mature platform-based target discovery has become.

Sources

• Recursion Partners with Genentech to Advance First Validated Neuro Target Discovered Through AI Map - Genetic Engineering and Biotechnology Newsgenengnews.com · Aug 5, 2026 · magyar
• Roche and Recursion: Pioneering AI-driven drug discovery | Eulerpooleulerpool.com · Aug 5, 2026 · magyar

Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.